GlaxoSmithKline

Game-changing hep B vaccine gets FDA nodThe first 2-dose hepatitis B vaccine, which was recently approved by FDA, is expected to be commercially available in early 2018.
The OD’s role with new diabetes drugsIt is important for eyecare providers to be familiar with these new drugs and findings. We often see patients with diabetes, metabolic syndrome, and high CV risk, and we are in a position to help counsel our patients about new treatments—and even suggest that appropriate patients have conversations with their primary-care physicians, endocrinologists and cardiologists.
GSK Launches More Effective Shingles Vaccine
GSK Launches More Effective Shingles VaccineWill Shingrix become the new go-to shingles vaccine?
Shingles vaccine wins approvalFDA approved the herpes zoster vaccine (Shingrix, GlaxoSmithKline) to treat shingles in adults aged 50 years and older.
Risks associated with omega-3 supplementation
Risks associated with omega-3 supplementationDuring my preoperative visit, my surgeon handed me a list of no less then 165 medications and supplements that I should stop taking 14 days prior to my surgery. Fish and krill oil were on the list, as were aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs)—as expected.
Differentiating ocular allergyOn the surface, eyecare providers may not fully appreciate the prevalence and complexity of ocular allergy and its clinical management; we learn that it is a relatively simple disease defined by ocular itch.
Brand-name patent losses raise pharma cost concernsA number of traditional brand-name pharmaceuticals have lost, or will lose, patent protection this year. What does this mean over the longer-term for controlling costs?
Pricing report blasts asthma drug costIn the latest controversy over drug pricing, an organization said that the price of GlaxoSmithKline’s Nucala (mepolizumab), an injectable indicated for severe asthma patients with eosinophilic inflammation, is far over-priced.
New rheumatoid arthritis therapies are comingFour new drugs and a biosimilar should be on your radar.
First-in-class biologic maintenance therapy approved for severe asthmaFDA approved mepolizumab (Nucala) as an add-on maintenance therapy for the treatment of patients with severe asthma who are 12 years and older and with an eosinophilic phenotype.